Analyst Francois Brisebois of LifeSci Capital maintained a Buy rating on Centessa Pharmaceuticals, retaining the price target of $49.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Francois Brisebois has given his Buy rating due to a combination of factors related to Centessa Pharmaceuticals’ promising developments in the field of sleep disorders. The company’s focus on orexin agonists, particularly their candidate ORX750, shows significant potential in treating conditions like narcolepsy and idiopathic hypersomnia. The emerging data on the efficacy and safety of these treatments positions Centessa favorably in a growing market.
Moreover, Centessa’s strategic planning for future studies, such as the ORX750 registrational program and ORX142 patient studies, indicates a strong pipeline that could lead to successful commercialization. Despite the company’s current cash burn rate, their financial position appears sustainable for the next two years, providing a solid foundation for continued research and development. These factors collectively contribute to the Buy rating, reflecting confidence in Centessa’s future growth prospects.
According to TipRanks, Brisebois is an analyst with an average return of -2.2% and a 36.99% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Kala Pharmaceuticals, Praxis Precision Medicines, and Centessa Pharmaceuticals.